CLAIM #11930 · Bristol-Myers Squibb Company (BMY) · 2024Q1 earnings call · Apr 25, 2024 · due Dec 31, 2025
“In 2024, we don't anticipate significant impact across our portfolio, across Eliquis, Revlimid or other brands. We do expect, though, more substantial changes to the Part D benefit next year since the products are impacted by the redesign.”
Adam Lenkowsky · Chief Commercialization Officer
PENDING
graded after results covering Dec 31, 2025 are reported
Verify independently
SEC filings for BMY ↗ · Claim quote is verbatim from the 2024Q1 earnings call.